[PubMed] [Google Scholar] 61

[PubMed] [Google Scholar] 61. al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol. 1995;34:1048C1054. [PubMed] [Google Scholar] 56. Distler O, Del Rosso A, Giacomelli R, et JNK-IN-7 al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis JNK-IN-7 Res. 2002;4:R11. [PMC free article] [PubMed] [Google Scholar] 57. Choi JJ, Min DJ, Cho ML, et al. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol. 2003;30:1529C1533. [PubMed] [Google Scholar] 58. Chitale S, Al-Mowallad AF, Wang Q, Kumar S, Herrick A. High circulating levels of VEGF-C suggest abnormal lymphangiogenesis in systemic sclerosis. Rheumatology (Oxford) 2008;47:1727C1728. [PubMed] [Google Scholar] 59. Viac J, Schmitt D, Claudy A. Plasma vascular endothelial growth factor levels in scleroderma are not correlated with disease activity. Acta Derm Venereol. 2000;80:383. [PubMed] [Google Scholar] 60. McLaughlin V, Humbert M, Coghlan G, Nash P, Steen V. NFKB1 Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology. 2009;48:iii25C31. [PubMed] [Google Scholar] 61. Ramirez A, Varga J. Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, JNK-IN-7 pathophysiology, evaluation, and management. Treat Respir Med. 2004;3:339C352. JNK-IN-7 [PubMed] [Google Scholar] 62. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972C2002. Ann Rheum Dis. 2007;66:940C944. [PMC free article] [PubMed] [Google Scholar] 63. Schmidt J, Launay D, Soudan B, et al. Assessment of plasma endothelin level measurement in systemic sclerosis. Rev Med Interne. 2007;28:371C376. [PubMed] [Google Scholar] 64. Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J. 2006;27:1485C1494. [PubMed] [Google Scholar] 65. Allanore Y, Borderie D, Avouac J, et al. High N-terminal probrain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum. 2008;58:284C291. [PubMed] [Google Scholar] 66. Dimitroulas T, Giannakoulas G, Karvounis H, et al. N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. Clin Rheumatol. 2008;27:655C658. [PubMed] [Google Scholar] 67. Simeoni S, Lippi G, Pucetti A, et al. N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol Int. 2008;28:657C660. [PubMed] [Google Scholar] 68. Mathai SC, Bueso M, Hummers K, et al. Disproportionate elevation of NT-proBNP in scleroderma-related pulmonary hypertension. Eur Respir J. 2009;35(1):95C104. [PubMed] [Google Scholar] 69. Wells AU, Steen V, Valentini G. Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology (Oxford) 2009;48:iii40C4. [PubMed] [Google Scholar] 70. Prasse A, Mller-Ouernheim J. Non-invasive biomarkers in pulmonary fibrosis. Respirology. 2009;14:788C795. [PubMed] [Google Scholar] 71. Kumnovics G, Minier T, Radics J, Plinks L, Berki T, Czirjk L. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. Clin Exp Rheumatol. 2008;26:414C420. [PubMed] [Google Scholar] 72. Yamane K, Ihn H, Kubo M, et al. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. J Rheumatol. 2000;27:930C934. [PubMed] [Google Scholar] 73. Sato S, Nagaoka T, Hasegawa M, Nishijima C, Takehara K. Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis. Dermatology. 2000;200:196C201. [PubMed] [Google Scholar] 74. Vesely R, Vargov V, Ravelli A, et al. Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis. J Rheumatol. 2004;31:795C800. [PubMed] [Google Scholar] 75. Yanaba K, Hasegawa M, Hamaguchi Y, Fujimoto M, Takehara K, Sato S. JNK-IN-7 Longitudinal analysis of serum KL-6 levels in patients.